SearchSearach Website
Close Searach

Search Website

A

Larger Smaller

A

Living Well With Low Vision Sponsored by Prevent Blindness
  • Info & News
  • Clinical Trials
  • Resources
  • Free Books
  • Patients’ Writings
  • About
  • Contact
  • Donate
Skip to content
Skip to content

Living Well With Low Vision

  • Info & News
  • Clinical Trials
  • Resources
  • Free Books
  • Patients’ Writings
  • About
  • Contact
  • Donate

News & Archive Categories

    Author: Dan Roberts

    New Drug Therapies Are Easing the Burden of Anti-VEGF Treatments

    Posted on June 15, 2022June 15, 2022 by Dan Roberts
  • June 15, 2022

    New Drug Therapies Are Easing the Burden of Anti-VEGF Treatments

    Treatments for neovascularization in the retina may be reduced to as few as two to four times per year.  New anti-VEGF drug therapies are now available for treatment of macular diseases. Over the past two years the U.S. Food and Drug Administration (FDA) has approved less invasive, less burdensome, and lower cost drugs and procedures. […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • Seeing Red

    Posted on June 7, 2022June 9, 2022 by Dan Roberts
  • June 7, 2022

    Seeing Red

    What makes us angry? As visually impaired and blind senior adults, we often find ourselves metaphorically seeing red when confronted by life without our most dominant sense. We are angered by our loss of independence, our inability to fight injustices, and by the ignorance or indifference of others.     Since most of us hale […]

      Also posted in
    • Daily Living
    • Essay
    • Latest News
    • Low Vision Rehabilitation
  • BYOOVIZ™ Launches in the U.S.

    Posted on June 2, 2022June 8, 2022 by Dan Roberts
  • June 2, 2022

    BYOOVIZ™ Launches in the U.S.

    Biogen Inc. and Samsung Bioepis Co., Ltd. has announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar of LUCENTIS® (ranibizumab) has been launched in the U.S. and will be commercially available on July 1, 2022. The list price will be $1,130 per injection, which is 40% lower than the current list price of LUCENTIS. The FDA approved BYOOVIZ […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • Does VUITY™ Treat AMD?

    Posted on March 20, 2022 by Dan Roberts
  • March 20, 2022

    Does VUITY™ Treat AMD?

    A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • APL-2 (pegcetacoplan) May Soon Become the First Treatment for Geographic Atrophy

    Posted on March 18, 2022March 20, 2022 by Dan Roberts
  • March 18, 2022

    APL-2 (pegcetacoplan) May Soon Become the First Treatment for Geographic Atrophy

    Apellis Pharmaceuticals has announced long term results from their Phase 3 DERBY and OAKS clinical studies, testing the efficacy and safety of APL-2 (now called intravitreal pegcetacoplan), as a treatment for geographic atrophy (GA). GA is also known as advanced dry age-related macular degeneration. In an analysis conducted at month 18 of the clinical studies, treatment […]

      Also posted in
    • Latest News
    • Research and Developments
  • 1
  • 2
  • 3
  • …
  • 23
  • Next Page »
Some Like it Neat, by Alex Vasquez
© All Rights Reserved
Footer Content Right

Receive News and Updates


 

We look to your generosity to support Prevent Blindness and keep our resources up to date.

Donate Now
  • Facebook
  • Twitter
Privacy Policy
Prevent Blindness

© 2018 Prevent Blindness. All rights reserved.